News

Qubot Technology has raised nearly RMB 100 million in a Pre-A+ round to advance Maxwell, its neurointerventional robotic platform combining magnetic distal-tip guidewire control, 4D-DSA imaging and a VLA foundation model, with the long-term goal of automated mechanical thrombectomy.

X-Cel Specialty Contacts and Essilor Custom Contacts have launched Lunara™, an FDA PMA-approved overnight orthokeratology lens made with Contamac’s 180 Dk Optimum Infinite® material, for temporary reduction of myopia up to −6.00 D with astigmatism up to 1.75 D.

Philips’ withdrawal of the V60 is opening a major replacement cycle in U.S. respiratory care. Mindray is targeting that installed base with the SV70 and a broader strategy built around workflow continuity, monitoring integration, local logistics and service support.

China’s NHSA has launched the first national basic medical insurance catalog for medical service items, covering 13 clinical categories. Together with standardized pricing items and consumables reimbursement reform, the policy is creating a more unified payment framework for medical device market access.

More than 600 clinicians, hospital managers, surgical robotics companies, researchers, investors and industry partners gathered in Beijing for the 4th Global Medical Robotics Conference, with two days of presentations and roundtables covering clinical application, product development, supply chains, overseas expansion, technology transfer, reimbursement and hospital adoption.

China has launched its 2026 high-end medical equipment promotion program, covering 16 priority products and one typical application scenario. Implantable brain-computer interfaces and remote laparoscopic surgery are among the newly highlighted areas, while participating products are required to have obtained Chinese medical device registration certificates.

China’s National Healthcare Security Administration has held a symposium with seven surgical robotics companies and five hospitals, highlighting several emerging policy directions for the sector, including pricing, DRG/DIP payment, real-world value assessment, data standards and remote surgery.

WEISEBOT is expanding its laparoscopic surgical robotics platform around procedure-specific clinical needs, with new developments in energy instruments, bipolar sealing, extended curved scissors and system integration aimed at supporting more complex general surgery workflows.

LifeTech Scientific’s Lantval™ Aortic Valve Replacement System has entered China’s NMPA innovative medical device special review pathway. The sutureless surgical valve combines a fully preloaded dry-valve design with self-expanding anchoring, with its pre-market registration clinical study expected to begin next.

China’s seventh national high-value medical consumables procurement round has produced proposed winning results, with 148 companies and 517 products selected across 23 gastrointestinal interventional product categories. The latest round also introduces revised pricing rules designed to curb excessive low-price competition.

A multicenter real-world study of Bausch + Lomb’s enVista Aspire™ and enVista Aspire™ Toric IOLs found strong distance vision and functional intermediate vision, with monocular UIVA of 20/32 or better achieved in 76.6% and 93.0% of eyes, respectively.

Liangyi unveiled three new product lines at CAOS 2026, including a universal positioning arm, a large-bone surgical power system and a high-speed surgical power system reaching 95,000 rpm, further expanding its upstream orthopedic robotics portfolio.

FUTURTEC’s ORTHBOT X knee replacement surgical navigation and positioning system has received CE MDR certification, extending the company’s European-certified orthopedic robotics portfolio from spine surgery into joint replacement.

China’s ophthalmic device industry spans several distinct markets, from hospital-purchased imaging systems and surgical platforms to volume-procured IOLs and consumer-facing myopia management products. This guide maps the major segments, companies and policy forces reshaping competition in 2026.

China’s medical imaging industry is moving rapidly into high-end technologies, from photon-counting CT and 5T MRI to advanced ultrasound and digital PET/CT. This guide maps the major modalities, Chinese competitors and procurement forces reshaping the market in 2026.

China’s cardiovascular device market now combines procurement-driven price pressure in mature categories with rapid innovation in structural heart, electrophysiology and advanced PCI. This guide maps the leading companies, technologies and policy forces reshaping competition across the industry in 2026.

NMPA approval allows a medical device onto the Chinese market, but it does not guarantee a hospital purchase. This guide explains how clinical demand, internal review, budgeting, tendering and centralized procurement shape access to China’s public hospitals—and where MedTech companies need to engage before a tender begins.

China’s Class I, II and III device categories may look familiar, but they do not map directly onto U.S. FDA or EU MDR classifications. This guide explains how the NMPA determines device risk, which authority handles each pathway, and what classification means for filing, registration and clinical evidence.

From high-end imaging and cardiovascular implants to diagnostics and surgical robotics, Chinese MedTech companies are moving rapidly up the value chain—and increasingly into global markets. This guide profiles 20 companies international executives should know, outlining what they make, where they compete and why they matter in 2026.

China’s MedTech market is no longer defined by size alone. In 2026, regulatory approval, hospital procurement, service pricing, reimbursement, localization and lifecycle economics are reshaping how devices reach patients. This article examines seven structural changes,and what they mean for global companies competing in China.

In the first half of 2026, China’s surgical robot market continued to develop across multiple system categories in parallel.

As of June 30, 2026, MedRobot’s analysis of publicly disclosed procurement awards from public hospitals in mainland China

As of June 30, 2026, MedRobot's analysis of publicly disclosed procurement awards from public hospitals across mainland China.

On the morning of June 12, 2026, the 2nd Global Cardiovascular Conference was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

On June 12, 2026, the 2nd Global Cardiovascular Conference (Global Cardiovascular Conference, GCC 2026) was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

On the afternoon of June 12, 2026, the 3rd Medical Device R&D Forum was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

On June 11, 2026, the 3rd Global MedTech Conference (Global MedTech Conference 2026) was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

When discussing cell and gene therapy, or CGT, ophthalmologists have in fact long stood at the forefront of the industry.

On June 11, 2026, the 3rd Global MedTech Conference was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

On June 11, 2026, the 2nd Global Ophthalmology Conference was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

On the afternoon of June 11, 2026, the 2nd Global Ophthalmology Conference was held at the Beijing Zhongguancun Exhibition Center Conference Hall.

TIROMU raised tens of millions of RMB in Pre-A funding to advance clinical trials and registration filing for its fundus injection surgical robot, while continuing R&D on next-generation ophthalmic microsurgery systems.

At the recently concluded 93rd China International Medical Equipment Fair (CMEF 2026), surgical robots once again emerged as a focal point.

China’s surgical robotics sector hits a turning point as Edge Medical Robotics reports RMB 301M gross profit and near profitability, signaling a shift from R&D-driven growth to sustainable commercialization.

On March 19, 2026, the Edge® Single-Port Robot (SP1000) received approval from the National Medical Products Administration (NMPA) for a change to its medical device registration.

Recently, Sightways Robotics announced that its self-developed EndoNimble™ Dual-Arm Surgical Robotic System has initiated human clinical research applications.

Edge Medical announced that its integrated multi-port, single-port and remote surgical robotic platform has been approved by China’s National Medical Products Administration (NMPA).

AK Medical’s K3+ total joint surgical robot has received market approval, becoming the first domestic system in China to support revision procedures across hip and knee indications.

With at least 611 systems sold in 2025, China’s surgical robot market is shifting from concept-driven growth to structured, clinically led expansion across multiple surgical specialties.

Edge Medical listed in Hong Kong at a HKD 23.2 billion market cap, signaling its entry into global benchmarking for surgical robotics.

In 2025, 52 NMPA approvals were granted to surgical robots developed by Chinese companies, including both new systems and indication expansions. Orthopedics accounted for the largest share, with 23 approvals.

China’s orthopedic surgical robot market reached at least 168 units in 2025, with domestic manufacturers leading the field and the industry entering a phase of rapid commercialization and clear differentiation.

Wiseking Medical has completed a B+ financing round to accelerate commercialization of its NMPA-approved laparoscopic surgical robot and advance next-generation system development.

Based on public hospital procurement disclosures, this report reviews 90 laparoscopic surgical robot awards in China in 2025, highlighting vendor concentration and evolving hospital adoption trends.

Yuanhua Robotics has secured NMPA approval for its YuanBOT-HX200 robotic knee system, bringing its 2025 approvals to 12 and reinforcing its momentum in end-to-end orthopedic robotics.

This report summarizes MedChina’s consolidated count of at least 313 surgical robotic systems sold or installed in 2024, based on public procurement records and partial manufacturer data.

Surgerii Robotics has restarted its A-share IPO process, marking a new phase of maturity for China’s single-port surgical robotics industry.

China approves its first robotic EP ablation system as TITIAN® brings remote, high-precision, and standardized workflows to interventional electrophysiology.

Toumai®’s fluorescence imaging system has received EU CE certification, bringing advanced multimode ICG visualization and enhanced intraoperative precision to global robotic surgery.

Cornerstone Robotics raised USD 200 million led by Hong Kong Investment Corporation to accelerate global expansion and next-generation surgical robot development.

Edge Medical’s MSP2000 Super System, the world’s first integrated Single and Multi-Port robotic platform, has received EU CE Mark approval, marking a major step in bringing Chinese surgical innovation to the global stage.

HUANOVA Biotechnology has raised tens of millions of RMB (approx. US$5–10 million) in Series A+ funding to advance its self-healing supramolecular biomaterial platform and accelerate clinical and global expansion.

Shanghai-based Angtai Weijing Medical Technology has raised hundreds of millions of RMB in Series B funding to advance its microsurgical robotics portfolio: ophthalmic, universal microsurgery, and endo-gastrointestinal systems.

Rossum Robot has completed the world’s first clinical installation of its R-Universal® Orthopedic Robotic System in Beijing, introducing a data-driven approach to complex fracture reduction.

Suzhou-based ophthalmic device company Microclear Medical has received CE-MDR certification for its SKY Full-Eye Imaging Platform and Ultra-Widefield Laser Fundus Camera, marking an important step in its global expansion.

Beijing-based medtech company New Cloud Medical announced the completion of its B+ financing round led by Dalton Venture, with participation from Taizhou Angel Fund and Qianfeng Investment. The funds will support clinical trials, regulatory approvals, and international expansion.

China’s NMPA has approved Lancet Robotics’ RobPath-Spine® and RobPath® knee navigation systems, marking a key step in the company’s surgical robotics portfolio.

The Global Medical Robotics Conference 2025 in Beijing concluded with the announcement of the annual Global Medical Robotics Awards, recognizing breakthroughs in technology, clinical applications, market impact, global expansion, supply chain, service partnerships, and rehabilitation robotics.

Yuanhua Robotics' KUNWU® surgical robot successfully assisted a knee replacement at 4,000 meters in Tibet, demonstrating sub-millimeter precision in low-oxygen conditions.

In July 2025, MedChina officially unveiled the 2025 Global MedTech 100 (GMT100), an authoritative annual ranking highlighting the world’s leading medical device companies based on their 2024 fiscal year revenue.

China’s magAssist is among 53 nominees for the prestigious 2025 Prix Galien USA “Best Startup” award, highlighting its innovative cardiopulmonary support devices and growing global recognition.

The Global Medical Robotics Conference 2025 will take place in Beijing from September 3–5, bringing together industry leaders to explore commercialization strategies, global expansion, clinical innovation, and ecosystem building for surgical robotics. This year’s edition features focused discussions, product showcases, and the MedRobot Awards recognizing key achievements across the field.

Medical device leader Mindray is pursuing a $1 billion Hong Kong IPO to accelerate its global expansion. With 45% of revenue from international markets, the company is transitioning from equipment exports to integrated healthcare solutions, supported by AI and localized manufacturing.

Between January and June 2025, 74 surgical robots were successfully procured by public hospitals across China. MedRobot presents a sectoral breakdown and insights into market trends, brand performance, and what to expect for the remainder of the year.

Chinese surgical robot maker Cornerstone Robotics is gaining global traction, with successful trials in the UK, partnerships in Singapore, and a cross-continent remote surgery demo, showcasing its ability to integrate into international healthcare systems.

Robotrak secures Series C funding to advance its high-precision ophthalmic imaging and laser systems, accelerating global commercialization of its Mona IV and Aglaia 577 platforms.

As AI takes over imaging analysis, post-op care, and even treatment planning, this article explores how the role of ophthalmologists is being redefined, and what it means to be a “good doctor” in the age of algorithms.

Rossum Robot CEO Yu Wang shares how the company is advancing orthopedic surgical robotics in China through technological innovation, clinical validation, and a pragmatic path to commercialization.

Lancet Robotics, a leading Chinese surgical robotics company, has raised a multi-million dollar A+ round to accelerate its product innovation and global market expansion.

Boston Scientific launches the Vercise Genus™ DBS System in China, introducing a next-generation, precision-driven solution for Parkinson’s care with real-time visualization and long-lasting therapeutic support.

Held on April 24 in Beijing, the Global Orthopedics Conference 2025 brings together global leaders in orthopedic innovation. Highlights include the release of the 2025 Global Orthopedics Innovation White Paper, keynote speeches by top experts, the Innovation Awards Ceremony, and policy insights from Beijing and Haidian District. Connect with device companies, surgeons, researchers, and industry stakeholders to explore the future of orthopedic care.

The medical aesthetics industry is undergoing rapid transformation, driven by breakthroughs in material science, biotechnology, laser technologies, and regenerative medicine. To foster global collaboration and accelerate the translation of innovation into practice, MeChina will host the 1st Global Aesthetic Technology Conference on June 12, 2025, in Beijing. The event will bring together global experts, innovators, investors, and regulators to explore emerging technologies, industrialization pathways, regulatory trends, and new market opportunities in aesthetic medicine.

​

Join China’s top ophthalmologists, researchers, and industry leaders at the Global Ophthalmology Conference 2025—the premier platform for cutting-edge insights, innovative technologies, and collaboration in eye care.

Medical technology stands at a crossroads of breakthrough and transformation. From AI-assisted diagnostics and intelligent therapeutic devices to regenerative medicine and digital therapeutics, innovation is reshaping how we detect, treat, and manage disease. To advance global collaboration across the medical technology value chain, from R&D to clinical application, MedChina warmly invites you to the 2nd Global MedTech Conference, taking place on July 17, 2025, in Beijing.

WEGO Blood Purification raises $150 million in its Shanghai Stock Exchange debut to boost smart manufacturing and R&D in China's dialysis market.

Explore the future of surgical robotics at the Global Medical Robotics Conference 2025, where global leaders converge to drive innovation, commercialization, and international growth.

China’s Surgerii Robotics single-port surgical robot achieves NMPA approval for four major specialties, enabling minimally invasive breakthroughs in thoracic and general surgery.

Xellar Biosystems secures strategic investment from XtalPi to pioneer AI-organ chip integration, aiming to revolutionize drug discovery with human-relevant, animal-free testing solutions.

At the Global Orthopedics Conference 2025, MedChina explores how this rising Chinese medtech company is driving precision, adaptability, and openness to reshape the future of surgery — from China to the world.

Gaush Meditech Ltd. announced NMPA approval for the Heidelberg ANTERION ophthalmic diagnostic system in China.

Beijing's 2025 policy breakthrough accelerates surgical robot adoption through R&D support, leasing models and DRG reforms, creating new opportunities in China's healthcare market.

Hangzhou-based Lynmou Medical has successfully closed its Series A funding round, raising tens of millions of RMB.

Beijing-based Yellwin Medical has completed its Series A++ funding round, raising tens of millions of RMB.

Venus MedTech is redefining global heart valve innovation with China's first FDA-approved device. Discover how its strategic pivot and clinical breakthroughs are reshaping structural heart treatment worldwide.